4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 Pite ≥99.5% (GC) faktori cho vann
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
Non Chimik | 4,6-Dichloro-2-Methylpyrimidine |
Sinonim | 2-Methyl-4,6-Dichloropyrimidine;2,4-Dichloro-6-Methylpyrimidine |
Nimewo CAS | 1780-26-3 |
Nimewo CAT | RF-PI687 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C5H4Cl2N2 |
Pwa molekilè | 163.00 |
Pwen k ap fonn | 41.5 ~ 45.5 ℃ (lit.) |
Solibilite (Soluble nan) | Methanol |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Poud kristalin blan oswa blan |
Pite / Metòd analiz | ≥99.5% (GC) |
Pèt sou siye | ≤0.50% |
Rezid sou ignisyon | ≤0.20% |
Single enpurte | ≤0.50% |
Enpurte total | ≤0.50% |
Tès Creole | Enterprise Standard |
Itilizasyon | Famasetik Entèmedyè;Dasatinib/Moxonidine Entèmedyè |
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) Wout pwosesis
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
![1](https://a395.goodao.net/uploads/15.jpg)
![](https://a395.goodao.net/uploads/23.jpg)
4,6-Dichloro-2-Methylpyrimidine (CAS: 1780-26-3) yo itilize nan sentèz entèmedyè pharmaceutique ak APIs.Pwodwi Preparasyon: Moxonidine (CAS: 75438-57-2);Dasatinib (CAS: 302962-49-8);Dasatinib monoidrat (CAS: 863127-77-9);4-Chloro-2,6-Dimethylpyrimidine (CAS: 4472-45-1);4-Amino-6-Chloro-2-Methylpyrimidine (CAS: 1749-68-4).Moxonidine se yon nouvo kalite dwòg antihypertansive, souvan itilize nan tretman tansyon wo esansyèl.Konpare ak pi gran antihypertensives santral ki aji, Moxonidine mare ak pi gwo afinite ak imidazoline I1-reseptè a pase ak α2-reseptè a.Dasatinib se yon inibitè kinaz onkogenik oral ki pisan, ki ka bloke siyal akselerasyon replikasyon selil kansè yo, nan mwa me 2009, Administrasyon Manje ak Medikaman Ameriken an (FDA) te apwouve fòmèlman vant dasatinib, li te klinikman itilize pou tretman divès kalite kwonik. lesemi myeloid (CML), ki gen ladan tretman lesemi myeloid kwonik ki rezistan oswa entoleran nan pwogram tretman yo ki gen ladan imatinib mesylate., Philadelphia kwomozòm-pozitif lesemi lenfoblastik egi (Ph + ALL) ak tretman pasyan ki gen timè solid.
-
4,6-Dichloro-2-Methylpyrimidine CAS 1780-26-3 P...
-
4-Methylpyrimidine CAS 3438-46-8 Pite ≥98.0% ...
-
2,4-Dichloro-5-Methylpyrimidine CAS 1780-31-0 P...
-
2-Amino-4,6-Dimethylpyrimidine CAS 767-15-7 Pur...
-
2-Amino-4-Methylpyrimidine CAS 108-52-1 Pite ...
-
2-Chloro-5-Methylpyrimidine CAS 22536-61-4 Puri...
-
2,4-Diamino-6-Hydroxypyrimidine CAS 56-06-4 Pur...
-
2,2′-Bipyrimidine CAS 34671-83-5 Pite ≥...
-
2,4-Diamino-6-Chloropyrimidine CAS 156-83-2 Pur...
-
2,4,6-Trichloropyrimidine CAS 3764-01-0 Essay ≥...
-
2,5-Diamino-4,6-Dichloropyrimidine CAS 55583-59...
-
2-Amino-4,6-Dichloropyrimidine CAS 56-05-3 Puri...
-
4,6-Dichloropyrimidine CAS 1193-21-1 Pite> 99...
-
4,6-Dichloro-5-Pyrimidinecarbaldehyde CAS 5305-...
-
4,6-Dichloro-5-Methoxypyrimidine CAS 5018-38-2 ...
-
4,6-Dichloropyrimidine-5-Carboxylic Asid CAS 87...